Jazz Pharmaceuticals has agreed to pay $935m for Chimerix, which focuses on the development of dordaviprone, a treatment for the rare brain tumour H3 K27M-mutant diffuse glioma. With Phase 2 results indicating positive effects from its use, Chimerix is seeking accelerated approval for the new formulation. FDA acceptance of the application has resulted in a provisional 18 August decision.
Week in review: How QR code attacks work and how to protect yourself, 10 must-reads for CISOs
Cybersecurity news over the past week highlighted the risks of increasing QR code attacks and social media scams. AI-powered simulations may enhance cybersecurity teams’ skills
